Cristina Blanco-Marchite

Cristina Blanco-Marchite

Auto-generated profile, based on publicly available information

Cristina Blanco-Marchite

Servicio de Oftalmología, Complejo Hospitalario Universitario de Albacete (Hospital Perpetuo Socorro), Albacete, Spain

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2009 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
MLM‐P López‐Garrido
M‐P López‐Garrido
CBC Blanco‐Marchite
C Blanco‐Marchite
FSF Sánchez‐Sánchez
F Sánchez‐Sánchez
ELE López‐Sánchez
E López‐Sánchez
VCV Chaqués‐Alepuz
V Chaqués‐Alepuz
Julio EscribanoJulio Escribano
Julio Escribano

23 February 2009
Verified
Journal Article
Open access
ECEzequiel Campos-Mollo
Ezequiel Campos-Mollo
MLMaría-Pilar López-Garrido
María-Pilar López-Garrido
CBCristina Blanco-Marchite
Cristina Blanco-Marchite
JGJulián García-Feijóo
Julián García-Feijóo
JPJesús Peralta
Jesús Peralta
Julio EscribanoJulio Escribano
Julio Escribano
To analyze the contributions of cytochrome P4501B1 (CYP1B1) mutations to primary congenital glaucoma (PCG) in Spanish patients. We analyzed, by polymerase chain reaction (PCR) DNA sequencing, the presence of promoter (−1 to −867) and exon CYP1B1 mutations in 38 unrelated Spanish probands affected by PCG. Functional analysis of nine identified mutations was performed measuring ethoxyresorufin O-deethylation activity and CYP1B1 stability in transiently transfected human embryonic kidney 293T (HEK-293-T) cells. We found a total of 16 different mutations in 13 (34.2%) index cases. The identified mutations included nine missense and three nonsense nucleotide changes, three small deletions, and a short duplication. Eleven probands were compound heterozygotes and two were heterozygotes. Six of the identified mutations were novel (A106D, E173X, F261L, E262X, W341X, and P513_K514del). Mutations T404fsX30 and R355fsX69 were the most prevalent among index cases and were detected in six (23.0%) and three (11.5%) patients, respectively. Functional analysis showed that the three nonsense mutants assayed (E173X, E262X, and W341X) and F261L were null alleles. Of the remaining mutants, four (P52L, G61E, Y81N, and E229K) showed catalytic activities ranging from 20% to 40% of wild-type CYP1B1 and high protein instability. Mutation P400S showed normal catalytic activity and moderate instability. These five mutants were classified as hypomorphic alleles. Patients carrying two null alleles showed severe phenotypes featured by very early PCG onset usually at birth or in the first month of life (0.6±0.9 months). Incomplete penetrance was detected in patients carrying hypomorphic alleles. Our data indicate that approximately one-third of Spanish patients with PCG carry loss-of-function CYP1B1 and show that null alleles are associated with the most severe phenotypes. Hypomorphic alleles may contribute to some cases of incomplete penetrance.

5 January 2021 in Orbit
Verified
Journal Article
Closed access
MDMónica Martínez Díaz
Mónica Martínez Díaz
SPSergio Copete Piqueras
Sergio Copete Piqueras
CMCristina Blanco Marchite
Cristina Blanco Marchite
KVKaveh Vahdani
Kaveh Vahdani
We describe a retrospective case report of dacryoadenitis associated with orbital inflammatory disease in a patient with confirmed SARS-CoV-2 infection. A 22-year-old previously fit and healthy male presented with 4-day history of right ocular redness, eyelid swelling and blurred vision associated with discomfort and pain in the lacrimal gland area. He was found to have right acute dacryoadenitis based on clinical examination and orbital imaging. One day after initiation of oral antibiotic and non-steroidal anti-inflammatory therapy, he developed worsening of the orbital inflammation and partial ophthalmoplegia. Oral steroids were commenced resulting in rapid resolution of symptoms within a few days and clinical stability at 2 months. The patient did not have any systemic features of COVID-19 but he was in close contact with his mother and with his partner who both had respiratory symptoms and tested positive for SARS-CoV-2 antigen (PCR testing) 4 weeks prior. PCR testing from nasopharyngeal swab was negative for SARS-CoV-2 RNA; however, the serological test was positive for IgM/IgG SARS-CoV-2 antibodies. Extensive laboratory workup including infectious and autoimmune screening and chest x-ray were unremarkable. Orbital inflammatory disease due to infectious process or immunological response may potentially occur in COVID-19 patients, although the causal relationship remains uncertain.

1 October 2011 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Closed access
PDF file
CBCristina Blanco-Marchite
Cristina Blanco-Marchite
FSFrancisco Sánchez-Sánchez
Francisco Sánchez-Sánchez
MLMaría-Pilar López-Garrido
María-Pilar López-Garrido
MIMercedes Iñigez-De-Onzoño
Mercedes Iñigez-De-Onzoño
FLFrancisco López-Martínez
Francisco López-Martínez
Julio EscribanoJulio Escribano
Julio Escribano
Purpose.: To investigate the role of WDR36 and P53 sequence variations in POAG susceptibility. Methods.: The authors performed a case-control genetic association study in 268 unrelated Spanish patients (POAG1) and 380 control subjects matched for sex, age, and ethnicity. WDR36 sequence variations were screened by either direct DNA sequencing or denaturing high-performance liquid chromatography. P53 polymorphisms p.R72P and c.97–147ins16bp were analyzed by single-nucleotide polymorphism (SNP) genotyping and PCR, respectively. Positive SNP and haplotype associations were reanalyzed in a second sample of 211 patients and in combined cases (n = 479). Results.: The authors identified almost 50 WDR36 sequence variations, of which approximately two-thirds were rare and one-third were polymorphisms. Approximately half the variants were novel. Eight patients (2.9%) carried rare mutations that were not identified in the control group (P = 0.001). Six Tag SNPs were expected to be structured in three common haplotypes. Haplotype H2 was consistently associated with the disease (P = 0.0024 in combined cases). According to a dominant model, genotypes containing allele P of the P53 p.R72P SNP slightly increased glaucoma risk. Glaucoma susceptibility associated with different WDR36 genotypes also increased significantly in combination with the P53 RP risk genotype, indicating the existence of a genetic interaction. For instance, the OR of the H2 diplotype estimated for POAG1 and combined cases rose approximately 1.6 times in the two-locus genotype H2/RP. Conclusions.: Rare WDR36 variants and the P53 p.R72P polymorphism behaved as moderate glaucoma risk factors in Spanish patients. The authors provide evidence for a genetic interaction between WDR36 and P53 variants in POAG susceptibility, although this finding must be confirmed in other populations.

11 July 2006
Verified
Journal Article
Closed access
MLMaría-Pilar López-Garrido
María-Pilar López-Garrido
FSFrancisco Sánchez-Sánchez
Francisco Sánchez-Sánchez
FLFrancisco López-Martínez
Francisco López-Martínez
Jose Daniel Aroca-AguilarJose Daniel Aroca-Aguilar
Jose Daniel Aroca-Aguilar
CBCristina Blanco-Marchite
Cristina Blanco-Marchite
Julio EscribanoJulio Escribano
Julio Escribano

1 July 2008 in Archivos de la Sociedad Española de Oftalmología
Verified
Journal Article
Open access
PDF file
CBC.I. Blanco-Marchite
C.I. Blanco-Marchite
LBL. Buznego-Suárez
L. Buznego-Suárez
MFM.A. Fagúndez-Vargas
M.A. Fagúndez-Vargas
MMM. Méndez-Llatas
M. Méndez-Llatas
PPP. Pozo-Martos
P. Pozo-Martos
Miller Fisher Syndrome (MFS) is the most frequent variant of the Guillain-Barré Syndrome. It is characterised by the classic triad of ophthalmoplegia, ataxia and areflexia. We present a case of a patient who developed these clinical findings 5 days after flu vaccination. Miller Fisher Syndrome is an unusual condition seen in ophthalmologic clinical practice. Although respiratory and digestive infections have been reported as antecedent infectious agents in MFS, it has not previously been described in relation to the flu vaccine.